Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

DTR, do we need a new definition?

Echols RM, Tillotson GS.

Clin Infect Dis. 2019 Mar 6. pii: ciz184. doi: 10.1093/cid/ciz184. [Epub ahead of print] No abstract available.

PMID:
30838418
2.

The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance.

Peyrani P, Mandell L, Torres A, Tillotson GS.

Expert Rev Respir Med. 2019 Feb;13(2):139-152. doi: 10.1080/17476348.2019.1562339. Epub 2018 Dec 30. Review.

PMID:
30596308
3.

Burden of antimicrobial resistance in an era of decreasing susceptibility.

Tillotson GS, Zinner SH.

Expert Rev Anti Infect Ther. 2017 Jul;15(7):663-676. doi: 10.1080/14787210.2017.1337508. Epub 2017 Jun 13.

PMID:
28580804
4.

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.

Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFy study group.

Lancet Infect Dis. 2017 Jul;17(7):735-744. doi: 10.1016/S1473-3099(17)30235-9. Epub 2017 Apr 28.

5.

Keeping the faith-reporting on antimicrobial resistance in an era of fake news.

Tillotson GS.

Lancet Infect Dis. 2017 May;17(5):473-474. doi: 10.1016/S1473-3099(17)30181-0. No abstract available.

PMID:
28447941
6.

Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.

Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM Jr.

Hosp Pract (1995). 2017 Feb;45(1):1-8. doi: 10.1080/21548331.2017.1279012. Epub 2017 Jan 18.

PMID:
28064542
7.

Trojan Horse Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance?

Tillotson GS.

Infect Dis (Auckl). 2016 Oct 11;9:45-52. eCollection 2016. Review.

8.

Rebuttal From Dr Tillotson.

Tillotson GS.

Chest. 2016 May;149(5):1133-5. doi: 10.1016/j.chest.2016.01.027. No abstract available.

PMID:
27157215
9.

COUNTERPOINT: Do Randomized Controlled Trials Ignore Needed Patient Populations? No.

Tillotson GS.

Chest. 2016 May;149(5):1130-2. doi: 10.1016/j.chest.2016.01.028. No abstract available.

PMID:
27157213
10.

Where in the world? The role of geography in antibiotic resistance and the potential impact in pulmonary infections.

Tillotson GS.

Postgrad Med. 2016 Jun;128(5):449-50. doi: 10.1080/00325481.2016.1185375. Epub 2016 May 21. No abstract available.

PMID:
27149001
11.

FDA and the safe and appropriate antibiotic use of fluoroquinolones.

Tillotson GS.

Lancet Infect Dis. 2016 Mar;16(3):e11-2. doi: 10.1016/S1473-3099(16)00051-7. No abstract available.

PMID:
26973315
12.

The Regulatory Pathway for Antifungal Drugs: A US Perspective.

Tillotson J, Tillotson GS.

Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S678-83. doi: 10.1093/cid/civ819.

PMID:
26567287
13.

Antibiotic Development and the Evolving Role of Pharmacodynamics - As Good as It Gets?

Tillotson GS, Zinner SH.

EBioMedicine. 2015 Jun 12;2(7):615-6. doi: 10.1016/j.ebiom.2015.06.010. eCollection 2015 Jul. No abstract available.

14.

New and alternative approaches to tackling antibiotic resistance.

Tillotson GS, Theriault N.

F1000Prime Rep. 2013 Dec 3;5:51. doi: 10.12703/P5-51. Review.

15.

Light at the end of the tunnel of antibiotic development.

Tillotson GS.

Lancet Infect Dis. 2013 Dec;13(12):1008-9. doi: 10.1016/S1473-3099(13)70316-5. Epub 2013 Nov 17. No abstract available.

PMID:
24252481
16.

Paul Ehrlich, a prescient pioneer in the field of antimicrobial chemotherapy: what did he foresee a century ago?

Tillotson GS, Zinner SH.

Expert Rev Anti Infect Ther. 2013 Feb;11(2):113-5. doi: 10.1586/eri.12.166. No abstract available.

PMID:
23409816
17.

Foreword: 10-year special edition.

Tillotson GS.

Expert Rev Anti Infect Ther. 2012 Nov;10(11):1219-20. doi: 10.1586/eri.12.130. No abstract available.

PMID:
23241175
18.

GAIN Act legislation: is it enough?

Tillotson GS.

Lancet Infect Dis. 2012 Nov;12(11):823-4. doi: 10.1016/S1473-3099(12)70260-8. No abstract available.

PMID:
23099071
19.

Susceptibility-testing criteria.

Tillotson GS, Tillotson J.

Lancet Infect Dis. 2011 Aug;11(8):584. doi: 10.1016/S1473-3099(11)70173-6. No abstract available.

PMID:
21798458
20.

Clostridium difficile--a moving target.

Tillotson GS, Tillotson J.

F1000 Med Rep. 2011;3:6. doi: 10.3410/M3-6. Epub 2011 Mar 1.

Supplemental Content

Loading ...
Support Center